公开(公告)号：EP1896453B1

公开(公告)日：2009-12-02

申请号：EP06785168.3

申请日：2006-06-19

申请人： Schering Corporation

发明人： ASLANIAN, Robert G. ,  BERLIN, Michael Y. ,  HUANG, Ying ,  MCCORMICK, Kevin D. ,  MUTAHI, Mwangi W. ,  SHIH, Neng-Yang ,  TING, Pauline, C. ,  TOM, Wing, C. ,  ZHENG, Junying

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61P3/04 ,  A61P29/00 ,  A61P37/00

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14

摘要： Disclosed are compounds of the formula (I); or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is -C(=O)-, -C(=S)-, -(CH2)q-, -C(=NOR7)- or -SO1-2-; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula (II); where ring A is a monoheteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

公开(公告)号：EP1966143A2

公开(公告)日：2008-09-10

申请号：EP06845817.3

申请日：2006-12-19

申请人： Schering Corporation

发明人： SOLOMON, Daniel M. ,  ASLANIAN, Robert G. ,  BERLIN, Michael Y. ,  DE LERA RUIZ, Manuel ,  MCCORMICK, Kevin D. ,  MUTAHI, Mwangi W. ,  TOM, Wing C.

IPC分类号： C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  A61K31/44 ,  A61P29/00

CPC分类号： C07D401/12 ,  C07D213/73 ,  C07D213/74 ,  C07D401/14 ,  C07D471/04

摘要： Disclosed are compounds of the formula Chemical formula (I) or a pharmaceutically acceptable salt thereof, wherein M2 is N; X is a bond, optionally substituted alkylene, alkenylene, -O-, -CH2N(R12)-, -N(R12)CH2-, -N(R12)-, -NHC(O)-, -OCH2-, -CH2O-, or -S(O)0-2-; and Y is -(CH2)1-2-, -C(=O)-, -C(=NOR13)- or -SO0-2-; or M1 is N; M2 is N or CH; X is a bond, alkylene, alkenylene, -C(O)-, -NHC(O)-, -OC(O)- or -S(O)1-2-; Y is -(CH2)1-2-, -C(=O)- or -SO0-2-; and when M2 is CH, Y is also Y is -O- or -C(=NOR13)-; Z is a bond or optionally substituted alkylene or alkenylene; U and W are CH, or one is CH and one is N; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; and compositions and methods of treating obesity, metabolic syndrome and a cognition deficit disorder, alone or in combination with other agents.

公开(公告)号：EP1896453A1

公开(公告)日：2008-03-12

申请号：EP06785168.3

申请日：2006-06-19

申请人： Schering Corporation

发明人： ASLANIAN, Robert G. ,  BERLIN, Michael Y. ,  HUANG, Ying ,  MCCORMICK, Kevin D. ,  MUTAHI, Mwangi W. ,  SHIH, Neng-Yang ,  TING, Pauline, C. ,  TOM, Wing, C. ,  ZHENG, Junying

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61P3/04 ,  A61P29/00 ,  A61P37/00

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14

摘要： Disclosed are compounds of the formula (I); or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is -C(=O)-, -C(=S)-, -(CH2)q-, -C(=NOR7)- or -SO1-2-; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula (II); where ring A is a monoheteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.